On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- MHLW Orders Label Revisions for Takecab to Include Pancytopenia to ADR List
October 30, 2019
- CEFP Members Prod Govt to Set Value-Based Target for Generic Promotion, but MHLW Wary
October 29, 2019
- Insurance Coverage of Cancer Genomic Profiling Tests in Early Stage Is Difficult: MHLW Official
October 29, 2019
- 1,419 ADR Victim Relief Claims Recieved in FY2018: MHLW
October 29, 2019
- 1st Topical JAK Inhibitor in Line for Japan Approval in January
October 28, 2019
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
- Xolair Up for Review for Pollen Allergy, Taltz for Ankylosing Spondylitis on Oct. 31
October 25, 2019
- Kenporen Pushes for No Health Coverage or Higher Copay for OTC-Like Drugs
October 25, 2019
- Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
- Chuikyo Payer Rep Moots Higher Prices for Biosames to Incentivize Biosimilar Development
October 24, 2019
- Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
October 24, 2019
- Discussions on PMD Law Amendment Bill Start in Extraordinary Diet
October 24, 2019
- Pharma Industry Seeks Cooperation from LDP Lawmakers on Pricing Challenges
October 23, 2019
- Industry to Politicians: Start Vaccine Discussions before Approval to Eliminate Lag Time
October 21, 2019
- Chuikyo OKs Insurance Coverage for Chugai’s Companion Diagnostic to Rozlytrek
October 21, 2019
- 1 Case of Person-to-Person Transmission of Xofluza-Resistant Flu Virus Confirmed in Japan
October 17, 2019
- MHLW Taking Public Comments on Rx-to-OTC for Mosapride
October 17, 2019
- 1st Topical JAK Inhibitor Up for MHLW Panel Review Oct. 25, Ono’s Cachexia Drug Still Shelved
October 15, 2019
- MHLW Orphan Status Dropped for Actemra, Rifampicin
October 15, 2019
- Less than 40% of Public Aware that Antibacterials Are Ineffective Against Common Cold: Govt Survey
October 15, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…